Risk of Osteoporosis Associated with Glucocorticoid Use in Pemphigus Vulgaris: Insights from a Retrospective Cohort Study

Merve Kaya; Gülhan Aksoy Saraç; Onur Acar; Selma Emre; Akın Aktaş

doi:10.5826/dpc.1502a5050

Risk of Osteoporosis Associated with Glucocorticoid Use in Pemphigus Vulgaris: Insights from a Retrospective Cohort Study

Authors

Merve Kaya Department of Dermatology, Bilkent City Hospital, Ankara, Turkey
Gülhan Aksoy Saraç Department of Dermatology, Bilkent City Hospital, Ankara, Turkey
Onur Acar Orhangazi District Health Directorate, Bursa, Turkey
Selma Emre Department of Dermatology, Ankara Yıldırım Beyazıt University, Medical School, Ankara, Turkey
Akın Aktaş Department of Dermatology, Ankara Yıldırım Beyazıt University, Medical School, Ankara, Turkey

Keywords:

pemphigus vulgaris, osteoporosis, bone mineral density

Abstract

Introduction: Pemphigus vulgaris (PV) is an autoimmune bullous disease affecting the skin and mucous membranes. Osteoporosis, a significant side effect of commonly used glucocorticoids in treatment, can adversely contribute to the existing morbidity.

Objectives: This study aims to assess the impact of glucocorticoid therapy on bone mineral density in patients with PV.

Methods: Patients newly diagnosed with PV were included in this study. Femur and lumbar T-scores, serum calcium, vitamin D, alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) levels were analyzed before and 1 year after therapy.

Results: Among 66 patients, the average time to diagnosis was 10.14 months, and the average daily dose of prednisone was 16.95 mg, with 63.6% of patients receiving medium doses. Our data showed no significant change in lumbar T-scores after one year of glucocorticoid treatment, but a significant decrease in femur density was observed. The decrease in femur T-scores was significant in the medium-dose group, while the lumbar T-scores decreased significantly in the high-dose group. There was no significant correlation between T-scores and gender, menopausal state, diagnosis time, or obesity. Additionally, vitamin D and LDH levels significantly increased after treatment, while changes in serum calcium and ALP levels were not significant.

Conclusion: Given the multiple factors that reduce bone mineral density in PV patients, the current strategies for glucocorticoid-induced osteoporosis prophylaxis in this group may need re-evaluation, with potential for additional recommendations to be included in pemphigus guidelines.

References

Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67(5):869-877. doi:10.1016/0092-8674(91)90360-b. PMID: 1720352.

Lin MS, Swartz SJ, Lopez A, Ding X, Fairley JA, Diaz LA. T lymphocytes from a subset of patients with pemphigus vulgaris respond to both desmoglein-3 and desmoglein-1. J Invest Dermatol. 1997;109(6):734-737. doi:10.1111/1523-1747.ep12340738. PMID: 9406813.

Zhao L, Chen Y, Wang M. The Global Incidence Rate of Pemphigus Vulgaris: A Systematic Review and Meta-Analysis. Dermatology. 2023;239(4):514-522. doi:10.1159/000530121. PMID: 36944327.

Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900-1913. doi:10.1111/jdv.16752. PMID: 32830877.

Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment--guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29(3):405-414. doi:10.1111/jdv.12772. PMID: 25338479.

Armas LA, Recker RR. Pathophysiology of osteoporosis: new mechanistic insights. Endocrinol Metab Clin North Am. 2012;41(3):475-486. doi:10.1016/j.ecl.2012.04.006. PMID: 22877425.

Humphrey MB, Russell L, Danila MI, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2023;75(12):2088-2102. doi:10.1002/art.42646. PMID: 37845798.

Park SY, Gong HS, Kim KM, et al. Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis. J Bone Metab. 2018;25(4):195-211. doi:10.11005/jbm.2018.25.4.195. PMID: 30574464.

Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718-722. doi:10.1136/ard.61.8.718. PMID: 12117678.

Wohl Y, Dreiher J, Cohen AD. Pemphigus and osteoporosis: a case-control study. Arch Dermatol. 2010;146(10):1126-1131. doi:10.1001/archdermatol.2010.257. PMID: 20956645.

Marzano AV, Trevisan V, Eller-Vainicher C, et al. Evidence for vitamin D deficiency and increased prevalence of fractures in autoimmune bullous skin diseases. Br J Dermatol. 2012;167(3):688-691. doi:10.1111/j.1365-2133.2012.10982.x. PMID: 22486251.

Marzano AV, Trevisan V, Cairoli E, et al. Vitamin D and skeletal health in autoimmune bullous skin diseases: a case control study. Orphanet J Rare Dis. 2015;10:8. Published 2015 Feb 3. doi:10.1186/s13023-015-0230-0. PMID: 25644263.

Echigo T, Hasegawa M, Shimada Y, Inaoki M, Takehara K, Sato S. Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases. Arch Dermatol Res. 2006;298(1):38-45. doi:10.1007/s00403-006-0661-5. PMID: 16583210.

Pacifici R. The immune system and bone. Arch Biochem Biophys. 2010;503(1):41-53. doi:10.1016/j.abb.2010.05.027. PMID: 20599675.

O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145(4):1835-1841. doi:10.1210/en.2003-0990. PMID: 14691012.

Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 2006;147(12):5592-5599. doi:10.1210/en.2006-0459. PMID: 16935844.

Richards JB, Rivadeneira F, Inouye M, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet. 2008;371(9623):1505-1512. doi:10.1016/S0140-6736(08)60599-1. PMID: 18455228.

van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383-1389. doi:10.1093/rheumatology/39.12.1383. PMID: 11136882.

Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341(8837):72-75. doi:10.1016/0140-6736(93)92555-8. PMID: 8093403.

Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332(12):767-773. doi:10.1056/NEJM199503233321202. PMID: 7862179.

Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167(2):155-160. doi:10.1001/archinte.167.2.155. PMID: 17242316.

Morin S, Leslie WD; Manitoba Bone Density Program. High bone mineral density is associated with high body mass index. Osteoporos Int. 2009;20(7):1267-1271. doi:10.1007/s00198-008-0797-6. PMID: 19034375.

Crepaldi G, Romanato G, Tonin P, Maggi S. Osteoporosis and body composition. J Endocrinol Invest. 2007;30(6 Suppl):42-47. PMID: 17721073.